000 01254 a2200361 4500
005 20250516090052.0
264 0 _c20120607
008 201206s 0 0 eng d
022 _a1532-6535
024 7 _a10.1038/clpt.2012.21
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aJohnson, J A
245 0 0 _aClopidogrel: a case for indication-specific pharmacogenetics.
_h[electronic resource]
260 _bClinical pharmacology and therapeutics
_cMay 2012
300 _a774-6 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, N.I.H., Extramural
650 0 4 _aAngioplasty, Balloon, Coronary
650 0 4 _aAryl Hydrocarbon Hydroxylases
_xgenetics
650 0 4 _aClopidogrel
650 0 4 _aCytochrome P-450 CYP2C19
650 0 4 _aGenotype
650 0 4 _aHumans
650 0 4 _aPharmacogenetics
650 0 4 _aPlatelet Aggregation Inhibitors
_xadverse effects
650 0 4 _aTiclopidine
_xadverse effects
700 1 _aRoden, D M
700 1 _aLesko, L J
700 1 _aAshley, E
700 1 _aKlein, T E
700 1 _aShuldiner, A R
773 0 _tClinical pharmacology and therapeutics
_gvol. 91
_gno. 5
_gp. 774-6
856 4 0 _uhttps://doi.org/10.1038/clpt.2012.21
_zAvailable from publisher's website
999 _c21712806
_d21712806